METTL3 and osteosarcoma: Li et al. (2020) found that low expression of FTO and METTL14 and high expression of METTL3, HNRNPA2B1, and YTHDF3 were related to the poor prognosis of osteosarcoma. The m6A “writer” METTL3 was demonstrated to promote radioresistance in pancreatic cancer (Taketo et al., 2018), hypopharyngeal squamous cell carcinoma (Wu et al., 2021), and glioma stem-like cells (Visvanathan et al., 2018).